CS391191A3 - Complex of p-anisoyl streptokinase and plasminogen, and pharmaceuticalscomprising thereof - Google Patents

Complex of p-anisoyl streptokinase and plasminogen, and pharmaceuticalscomprising thereof Download PDF

Info

Publication number: CS391191A3
Authority: CS; Czechoslovakia
Prior art keywords: plasminogen; complex; streptokinase; anisoyl; derivative
Prior art date: 1979-11-05

Application number

CS913911A

Other languages

Czech (cs)

English (en)

Inventor

Richard A G Smith

John G Winchester

Original Assignee

Beecham Group Plc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1979-11-05

Filing date

1991-12-19

Publication date

1992-08-12

1991-12-19 Application filed by Beecham Group Plc filed Critical Beecham Group Plc

1992-08-12 Publication of CS391191A3 publication Critical patent/CS391191A3/cs

Links

108010023197 Streptokinase Proteins 0.000 title claims description 43
229960005202 streptokinase Drugs 0.000 title claims description 43
-1 p-anisoyl Chemical group 0.000 title claims description 37
102000013566 Plasminogen Human genes 0.000 title claims description 34
108010051456 Plasminogen Proteins 0.000 title claims description 34
238000000034 method Methods 0.000 claims description 13
239000000203 mixture Substances 0.000 claims description 13
208000007536 Thrombosis Diseases 0.000 claims description 9
241000282414 Homo sapiens Species 0.000 claims description 7
108010087750 lysyl-plasminogen Proteins 0.000 claims description 7
238000002347 injection Methods 0.000 claims description 6
239000007924 injection Substances 0.000 claims description 6
239000008194 pharmaceutical composition Substances 0.000 claims description 5
238000001990 intravenous administration Methods 0.000 claims description 4
241000282412 Homo Species 0.000 claims description 3
238000011282 treatment Methods 0.000 claims description 3
239000003937 drug carrier Substances 0.000 claims description 2
230000000069 prophylactic effect Effects 0.000 claims description 2
230000001225 therapeutic effect Effects 0.000 claims description 2
108091000080 Phosphotransferase Proteins 0.000 claims 1
230000037396 body weight Effects 0.000 claims 1
239000008196 pharmacological composition Substances 0.000 claims 1
102000020233 phosphotransferase Human genes 0.000 claims 1
230000002265 prevention Effects 0.000 claims 1
238000006243 chemical reaction Methods 0.000 description 22
108090000790 Enzymes Proteins 0.000 description 16
102000004190 Enzymes Human genes 0.000 description 16
229940088598 enzyme Drugs 0.000 description 16
230000007062 hydrolysis Effects 0.000 description 15
238000006460 hydrolysis reaction Methods 0.000 description 15
230000003197 catalytic effect Effects 0.000 description 14
239000000243 solution Substances 0.000 description 13
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 9
230000003213 activating effect Effects 0.000 description 9
125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 8
125000001424 substituent group Chemical group 0.000 description 8
239000000463 material Substances 0.000 description 7
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 6
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
238000002360 preparation method Methods 0.000 description 6
239000000047 product Substances 0.000 description 6
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
241001465754 Metazoa Species 0.000 description 5
239000012736 aqueous medium Substances 0.000 description 5
239000003795 chemical substances by application Substances 0.000 description 5
230000009089 cytolysis Effects 0.000 description 5
230000002255 enzymatic effect Effects 0.000 description 5
239000003527 fibrinolytic agent Substances 0.000 description 5
230000003480 fibrinolytic effect Effects 0.000 description 5
239000000594 mannitol Substances 0.000 description 5
235000010355 mannitol Nutrition 0.000 description 5
238000002156 mixing Methods 0.000 description 5
229940012957 plasmin Drugs 0.000 description 5
239000000758 substrate Substances 0.000 description 5
KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 4
229930195725 Mannitol Natural products 0.000 description 4
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
206010047249 Venous thrombosis Diseases 0.000 description 4
230000004913 activation Effects 0.000 description 4
239000003054 catalyst Substances 0.000 description 4
230000020176 deacylation Effects 0.000 description 4
238000005947 deacylation reaction Methods 0.000 description 4
239000000499 gel Substances 0.000 description 4
238000001802 infusion Methods 0.000 description 4
239000003755 preservative agent Substances 0.000 description 4
108090000765 processed proteins & peptides Proteins 0.000 description 4
239000002904 solvent Substances 0.000 description 4
241000282472 Canis lupus familiaris Species 0.000 description 3
102000008100 Human Serum Albumin Human genes 0.000 description 3
108091006905 Human Serum Albumin Proteins 0.000 description 3
239000004472 Lysine Substances 0.000 description 3
241000283973 Oryctolagus cuniculus Species 0.000 description 3
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
125000003647 acryloyl group Chemical group O=C([*])C([H])=C([H])[H] 0.000 description 3
125000002252 acyl group Chemical group 0.000 description 3
238000005917 acylation reaction Methods 0.000 description 3
230000000903 blocking effect Effects 0.000 description 3
239000003153 chemical reaction reagent Substances 0.000 description 3
239000010630 cinnamon oil Substances 0.000 description 3
150000001875 compounds Chemical class 0.000 description 3
230000000694 effects Effects 0.000 description 3
239000000706 filtrate Substances 0.000 description 3
238000004108 freeze drying Methods 0.000 description 3
229960003646 lysine Drugs 0.000 description 3
229920001184 polypeptide Polymers 0.000 description 3
102000004196 processed proteins & peptides Human genes 0.000 description 3
239000003223 protective agent Substances 0.000 description 3
230000001681 protective effect Effects 0.000 description 3
235000018102 proteins Nutrition 0.000 description 3
102000004169 proteins and genes Human genes 0.000 description 3
108090000623 proteins and genes Proteins 0.000 description 3
238000010561 standard procedure Methods 0.000 description 3
239000000126 substance Substances 0.000 description 3
WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 2
ZEYHEAKUIGZSGI-UHFFFAOYSA-N 4-methoxybenzoic acid Chemical compound COC1=CC=C(C(O)=O)C=C1 ZEYHEAKUIGZSGI-UHFFFAOYSA-N 0.000 description 2
241000723347 Cinnamomum Species 0.000 description 2
ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 2
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
BVHLGVCQOALMSV-JEDNCBNOSA-N L-lysine hydrochloride Chemical compound Cl.NCCCC[C@H](N)C(O)=O BVHLGVCQOALMSV-JEDNCBNOSA-N 0.000 description 2
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
230000010933 acylation Effects 0.000 description 2
125000000217 alkyl group Chemical group 0.000 description 2
230000015572 biosynthetic process Effects 0.000 description 2
229930016911 cinnamic acid Natural products 0.000 description 2
235000013985 cinnamic acid Nutrition 0.000 description 2
235000017803 cinnamon Nutrition 0.000 description 2
238000003776 cleavage reaction Methods 0.000 description 2
238000001962 electrophoresis Methods 0.000 description 2
239000012530 fluid Substances 0.000 description 2
239000012634 fragment Substances 0.000 description 2
238000002955 isolation Methods 0.000 description 2
239000007788 liquid Substances 0.000 description 2
235000018977 lysine Nutrition 0.000 description 2
WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 2
125000000636 p-nitrophenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)[N+]([O-])=O 0.000 description 2
229940127126 plasminogen activator Drugs 0.000 description 2
239000000843 powder Substances 0.000 description 2
230000002335 preservative effect Effects 0.000 description 2
230000008569 process Effects 0.000 description 2
125000006239 protecting group Chemical group 0.000 description 2
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
230000007017 scission Effects 0.000 description 2
239000011780 sodium chloride Substances 0.000 description 2
239000001488 sodium phosphate Substances 0.000 description 2
229910000162 sodium phosphate Inorganic materials 0.000 description 2
230000003335 steric effect Effects 0.000 description 2
108010008962 streptokinase-plasminogen complex Proteins 0.000 description 2
229960000103 thrombolytic agent Drugs 0.000 description 2
RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 2
PGOHTUIFYSHAQG-LJSDBVFPSA-N (2S)-6-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-1-[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-4-methylsulfanylbutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]propanoyl]pyrrolidine-2-carbonyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]-4-methylpentanoyl]amino]-3-sulfanylpropanoyl]amino]-4-methylsulfanylbutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-hydroxybutanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-hydroxypropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxybutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-oxopentanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-oxopentanoyl]amino]-3-phenylpropanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-oxobutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-4-carboxybutanoyl]amino]-5-oxopentanoyl]amino]hexanoic acid Chemical compound CSCC[C@H](N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(O)=O PGOHTUIFYSHAQG-LJSDBVFPSA-N 0.000 description 1
CFOQGBUQTOGYKI-UHFFFAOYSA-N (4-nitrophenyl) 4-(diaminomethylideneamino)benzoate Chemical compound C1=CC(N=C(N)N)=CC=C1C(=O)OC1=CC=C([N+]([O-])=O)C=C1 CFOQGBUQTOGYKI-UHFFFAOYSA-N 0.000 description 1
ODIGIKRIUKFKHP-UHFFFAOYSA-N (n-propan-2-yloxycarbonylanilino) acetate Chemical group CC(C)OC(=O)N(OC(C)=O)C1=CC=CC=C1 ODIGIKRIUKFKHP-UHFFFAOYSA-N 0.000 description 1
UOBYKYZJUGYBDK-UHFFFAOYSA-M 2-naphthoate Chemical compound C1=CC=CC2=CC(C(=O)[O-])=CC=C21 UOBYKYZJUGYBDK-UHFFFAOYSA-M 0.000 description 1
NMIJQVGEQUAMTN-UHFFFAOYSA-N 3-carbamimidoyl-6-methyl-2-phenylbenzoic acid Chemical compound CC1=C(C(=C(C=C1)C(=N)N)C2=CC=CC=C2)C(=O)O NMIJQVGEQUAMTN-UHFFFAOYSA-N 0.000 description 1
125000001999 4-Methoxybenzoyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1OC([H])([H])[H])C(*)=O 0.000 description 1
FUWREDLHIUFGIA-UHFFFAOYSA-N 4-acetamido-4-carbamimidoyl-2-phenylcyclohexa-1,5-diene-1-carboxylic acid Chemical compound CC(=O)NC1(CC(=C(C=C1)C(=O)O)C2=CC=CC=C2)C(=N)N FUWREDLHIUFGIA-UHFFFAOYSA-N 0.000 description 1
VGCVGWCATXMJPC-UHFFFAOYSA-N 4-butyl-4-carbamimidoyl-2-phenylcyclohexa-1,5-diene-1-carboxylic acid Chemical compound CCCCC1(CC(=C(C=C1)C(=O)O)C2=CC=CC=C2)C(=N)N VGCVGWCATXMJPC-UHFFFAOYSA-N 0.000 description 1
VRJWMZFTJMHQJF-UHFFFAOYSA-N 4-carbamimidoyl-2-methoxy-3-phenylbenzoic acid Chemical compound COC1=C(C=CC(=C1C2=CC=CC=C2)C(=N)N)C(=O)O VRJWMZFTJMHQJF-UHFFFAOYSA-N 0.000 description 1
KOVBSYHWYZUXQZ-UHFFFAOYSA-N 4-carbamimidoyl-3,4-dimethyl-2-phenylcyclohexa-1,5-diene-1-carboxylic acid Chemical compound CC1C(=C(C=CC1(C)C(=N)N)C(=O)O)C2=CC=CC=C2 KOVBSYHWYZUXQZ-UHFFFAOYSA-N 0.000 description 1
RERGZUQQJQQETF-UHFFFAOYSA-N 4-carbamimidoyl-4-ethoxy-2-phenylcyclohexa-1,5-diene-1-carboxylic acid Chemical compound CCOC1(CC(=C(C=C1)C(=O)O)C2=CC=CC=C2)C(=N)N RERGZUQQJQQETF-UHFFFAOYSA-N 0.000 description 1
HITZTFCPBZDCCV-UHFFFAOYSA-N 4-carbamimidoyl-4-methoxy-3-methyl-2-phenylcyclohexa-1,5-diene-1-carboxylic acid Chemical compound CC1C(=C(C=CC1(C(=N)N)OC)C(=O)O)C2=CC=CC=C2 HITZTFCPBZDCCV-UHFFFAOYSA-N 0.000 description 1
BBYDXOIZLAWGSL-UHFFFAOYSA-M 4-fluorobenzoate Chemical compound [O-]C(=O)C1=CC=C(F)C=C1 BBYDXOIZLAWGSL-UHFFFAOYSA-M 0.000 description 1
102000007469 Actins Human genes 0.000 description 1
108010085238 Actins Proteins 0.000 description 1
ATRRKUHOCOJYRX-UHFFFAOYSA-N Ammonium bicarbonate Chemical compound [NH4+].OC([O-])=O ATRRKUHOCOJYRX-UHFFFAOYSA-N 0.000 description 1
229910000013 Ammonium bicarbonate Inorganic materials 0.000 description 1
JPIXEHZJYIUJPE-UHFFFAOYSA-N C(N)(=N)C1(C(C(=C(C(=O)O)C=C1C)C1=CC=CC=C1)C)OC Chemical compound C(N)(=N)C1(C(C(=C(C(=O)O)C=C1C)C1=CC=CC=C1)C)OC JPIXEHZJYIUJPE-UHFFFAOYSA-N 0.000 description 1
241000282465 Canis Species 0.000 description 1
WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 1
QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 1
241000282324 Felis Species 0.000 description 1
101710196208 Fibrinolytic enzyme Proteins 0.000 description 1
101000605403 Homo sapiens Plasminogen Proteins 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
235000019766 L-Lysine Nutrition 0.000 description 1
ZYQDEQFTXCPPJR-UHFFFAOYSA-N NC(=N)C1=CC=C(C(O)=O)C(C=2C=CC=CC=2)=C1 Chemical compound NC(=N)C1=CC=C(C(O)=O)C(C=2C=CC=CC=2)=C1 ZYQDEQFTXCPPJR-UHFFFAOYSA-N 0.000 description 1
108091005804 Peptidases Proteins 0.000 description 1
108010001014 Plasminogen Activators Proteins 0.000 description 1
102000001938 Plasminogen Activators Human genes 0.000 description 1
239000004365 Protease Substances 0.000 description 1
208000010378 Pulmonary Embolism Diseases 0.000 description 1
102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
229920002684 Sepharose Polymers 0.000 description 1
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
102000002262 Thromboplastin Human genes 0.000 description 1
108010000499 Thromboplastin Proteins 0.000 description 1
239000012190 activator Substances 0.000 description 1
150000001262 acyl bromides Chemical class 0.000 description 1
150000001263 acyl chlorides Chemical group 0.000 description 1
125000004423 acyloxy group Chemical group 0.000 description 1
238000001042 affinity chromatography Methods 0.000 description 1
125000005236 alkanoylamino group Chemical group 0.000 description 1
125000003545 alkoxy group Chemical group 0.000 description 1
150000001412 amines Chemical class 0.000 description 1
229960002684 aminocaproic acid Drugs 0.000 description 1
235000012538 ammonium bicarbonate Nutrition 0.000 description 1
239000001099 ammonium carbonate Substances 0.000 description 1
239000003708 ampul Substances 0.000 description 1
230000003444 anaesthetic effect Effects 0.000 description 1
229940071248 anisate Drugs 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
125000003118 aryl group Chemical group 0.000 description 1
230000001174 ascending effect Effects 0.000 description 1
230000008901 benefit Effects 0.000 description 1
239000002981 blocking agent Substances 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
239000008280 blood Substances 0.000 description 1
210000004556 brain Anatomy 0.000 description 1
YYXYBWIDIWTCGS-UHFFFAOYSA-N chembl363685 Chemical compound NC(=N)C1=CC=C(O)C=C1 YYXYBWIDIWTCGS-UHFFFAOYSA-N 0.000 description 1
230000009918 complex formation Effects 0.000 description 1
239000012141 concentrate Substances 0.000 description 1
238000009833 condensation Methods 0.000 description 1
230000005494 condensation Effects 0.000 description 1
UKJLNMAFNRKWGR-UHFFFAOYSA-N cyclohexatrienamine Chemical group NC1=CC=C=C[CH]1 UKJLNMAFNRKWGR-UHFFFAOYSA-N 0.000 description 1
238000000502 dialysis Methods 0.000 description 1
125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 1
ZMXDDKWLCZADIW-UHFFFAOYSA-N dimethylformamide Substances CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 1
PXEDJBXQKAGXNJ-QTNFYWBSSA-L disodium L-glutamate Chemical compound [Na+].[Na+].[O-]C(=O)[C@@H](N)CCC([O-])=O PXEDJBXQKAGXNJ-QTNFYWBSSA-L 0.000 description 1
229940079593 drug Drugs 0.000 description 1
239000003814 drug Substances 0.000 description 1
238000001704 evaporation Methods 0.000 description 1
230000008020 evaporation Effects 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
210000003191 femoral vein Anatomy 0.000 description 1
230000020764 fibrinolysis Effects 0.000 description 1
239000011521 glass Substances 0.000 description 1
229910052736 halogen Inorganic materials 0.000 description 1
150000002367 halogens Chemical group 0.000 description 1
230000002949 hemolytic effect Effects 0.000 description 1
229940106780 human fibrinogen Drugs 0.000 description 1
125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
230000003993 interaction Effects 0.000 description 1
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
LPUQAYUQRXPFSQ-DFWYDOINSA-M monosodium L-glutamate Chemical compound [Na+].[O-]C(=O)[C@@H](N)CCC(O)=O LPUQAYUQRXPFSQ-DFWYDOINSA-M 0.000 description 1
235000013923 monosodium glutamate Nutrition 0.000 description 1
125000001038 naphthoyl group Chemical group C1(=CC=CC2=CC=CC=C12)C(=O)* 0.000 description 1
150000007530 organic bases Chemical group 0.000 description 1
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
230000004962 physiological condition Effects 0.000 description 1
239000003495 polar organic solvent Substances 0.000 description 1
238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
239000002244 precipitate Substances 0.000 description 1
239000002243 precursor Substances 0.000 description 1
238000011045 prefiltration Methods 0.000 description 1
230000000019 pro-fibrinolytic effect Effects 0.000 description 1
238000011321 prophylaxis Methods 0.000 description 1
230000009467 reduction Effects 0.000 description 1
150000003839 salts Chemical class 0.000 description 1
230000003248 secreting effect Effects 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
239000011734 sodium Substances 0.000 description 1
229940073490 sodium glutamate Drugs 0.000 description 1
239000007787 solid Substances 0.000 description 1
239000008227 sterile water for injection Substances 0.000 description 1
230000001954 sterilising effect Effects 0.000 description 1
238000004659 sterilization and disinfection Methods 0.000 description 1
238000001356 surgical procedure Methods 0.000 description 1
239000000725 suspension Substances 0.000 description 1
238000007910 systemic administration Methods 0.000 description 1
238000012360 testing method Methods 0.000 description 1
238000004809 thin layer chromatography Methods 0.000 description 1
230000009424 thromboembolic effect Effects 0.000 description 1
230000002537 thrombolytic effect Effects 0.000 description 1
238000004448 titration Methods 0.000 description 1
238000000108 ultra-filtration Methods 0.000 description 1
210000003462 vein Anatomy 0.000 description 1
239000000341 volatile oil Substances 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
- C07K14/3153—Streptokinase
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/99—Enzyme inactivation by chemical treatment
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides

Landscapes

Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Genetics & Genomics (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Zoology (AREA)
Molecular Biology (AREA)
Wood Science & Technology (AREA)
Biochemistry (AREA)
General Chemical & Material Sciences (AREA)
Biotechnology (AREA)
Biomedical Technology (AREA)
General Engineering & Computer Science (AREA)
Gastroenterology & Hepatology (AREA)
Microbiology (AREA)
Biophysics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Chemical Kinetics & Catalysis (AREA)
Animal Behavior & Ethology (AREA)
Hematology (AREA)
Diabetes (AREA)
Veterinary Medicine (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Enzymes And Modification Thereof (AREA)
Medicinal Preparation (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

CS913911A 1979-11-05 1991-12-19 Complex of p-anisoyl streptokinase and plasminogen, and pharmaceuticalscomprising thereof CS391191A3 (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
GB7938279		1979-11-05

Publications (1)

Publication Number	Publication Date
CS391191A3 true CS391191A3 (en)	1992-08-12

Family

ID=10508982

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
CS913911A CS391191A3 (en)	1979-11-05	1991-12-19	Complex of p-anisoyl streptokinase and plasminogen, and pharmaceuticalscomprising thereof
CS913919A CS391991A3 (en)	1979-11-05	1991-12-19	Enzyme derivatives, process of their preparation and pharmaceuticals comprising thereof

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
CS913919A CS391991A3 (en)	1979-11-05	1991-12-19	Enzyme derivatives, process of their preparation and pharmaceuticals comprising thereof

Country Status (18)

Country	Link
US (1)	US4808405A (fr)
EP (1)	EP0028489B1 (fr)
JP (1)	JPS5678590A (fr)
AR (1)	AR224786A1 (fr)
CA (1)	CA1174621A (fr)
CS (2)	CS391191A3 (fr)
DE (1)	DE3065190D1 (fr)
DK (1)	DK158994C (fr)
ES (1)	ES496586A0 (fr)
GR (1)	GR72121B (fr)
HK (1)	HK65886A (fr)
HU (1)	HU185223B (fr)
IE (1)	IE50174B1 (fr)
IL (1)	IL61408A (fr)
NL (1)	NL930029I2 (fr)
NO (1)	NO163867C (fr)
NZ (1)	NZ195469A (fr)
ZA (1)	ZA806641B (fr)

Families Citing this family (78)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0091240B1 (fr) *	1982-04-07	1985-12-27	Beecham Group Plc	Dérivés d'enzymes, procédé pour leur préparation et compositions pharmaceutiques les contenant
EP0125269A1 (fr) *	1982-11-11	1984-11-21	Beecham Group Plc	Composes pharmaceutiquement actifs
GB8400653D0 (en) *	1984-01-11	1984-02-15	Beecham Group Plc	Conjugates
GB8430253D0 (en) *	1984-11-30	1985-01-09	Beecham Group Plc	Compounds
US5231006A (en) *	1986-10-16	1993-07-27	Behringwerke Aktiengesellschaft	Method for the determination of plasminogen
US5256642A (en) *	1988-04-01	1993-10-26	The Johns Hopkins University	Compositions of soluble complement receptor 1 (CR1) and a thrombolytic agent, and the methods of use thereof
JPH0296536A (ja) *	1988-09-29	1990-04-09	Green Cross Corp:The	プラスミノゲン乾燥製剤
FI915149A0 (fi) *	1989-05-01	1991-10-31	Univ Notre Dame Du Lac	Foerfarande och material foer expression av humant plasminogen i ett eukaryotiskt cellsystem som saknar en laegesspecifik plasminogenaktivator.
EP0397366A1 (fr) *	1989-05-09	1990-11-14	The Board Of Regents Of The University Of Oklahoma	Streptokinases hybrides avec des domaines de liaison pour la fibrine et méthodes pour leur synthèse
ATE135200T1 (de) *	1989-05-17	1996-03-15	Res Corp Technologies Inc	Verfahren und zusammensetzung zur thrombosebehandlung beim säugetier
CA2027936C (fr)	1989-10-23	2001-07-24	Smithkline Beecham Corporation	Peptides cycliques anti-agregants
US5087572A (en) *	1989-12-01	1992-02-11	Genentech, Inc.	Dna encoding human plasminogen modified at the cleavage site
US5190756A (en) *	1989-12-01	1993-03-02	Genentech, Inc.	Methods and materials for expression of human plasminogen variant
GB8928163D0 (en) *	1989-12-13	1990-02-14	Beecham Group Plc	Novel treatment
US6458360B1 (en)	1990-04-25	2002-10-01	The Johns Hopkins University	Soluble complement regulatory molecules
US5187069A (en) *	1990-08-06	1993-02-16	Henry Ford Health System	Active site labelling of plasminogen
AU1873092A (en) *	1991-04-09	1992-11-17	Brigham And Women's Hospital	Chimeric molecule with plasminogen activator activity and affinity for atherosclerotic plaques
US5520912A (en) *	1993-07-02	1996-05-28	Immuno Aktiengesellschaft	Prevention and treatment of ischemic events and reperfusion injury resulting therefrom using lys-plasminogen
DE4411143C2 (de) *	1994-03-30	1996-08-01	Immuno Ag	Thrombosemittel
US5760028A (en) *	1995-12-22	1998-06-02	The Dupont Merck Pharmaceutical Company	Integrin receptor antagonists
US6004955A (en) *	1996-08-15	1999-12-21	Dupont Pharmaceuticals Company	Cyclic carbamates and isoxazolidines as IIb/IIIa antagonists
HRP980334A2 (en)	1997-06-19	1999-04-30	Mimi Lifen Quan	INHIBITORS OF FACTOR Xa WITH A NEUTRAL P1 SPECIFICITY GROUP
EP1203026A4 (fr) *	1999-07-29	2005-03-16	Dyax Corp	Fractions se liant la fibrine
US6388073B1 (en)	2000-07-26	2002-05-14	Shire Us Inc.	Method for the manufacture of anagrelide
KR20010000669A (ko) *	2000-10-12	2001-01-05	김기환	스트렙토키나제와 사람 혈청알부민의 포합체를유효성분으로 함유하는 전신투여용 지속성 혈전 용해제
US6984373B2 (en) *	2000-12-23	2006-01-10	Dyax Corp.	Fibrin binding moieties useful as imaging agents
AU2002341693B2 (en)	2001-09-21	2008-05-29	Bristol-Myers Squibb Holdings Ireland Unlimited Company	Lactam-containing compounds and derivatives thereof as factor Xa inhibitors
US7550499B2 (en)	2004-05-12	2009-06-23	Bristol-Myers Squibb Company	Urea antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions
US7700608B2 (en)	2004-08-04	2010-04-20	Shire Holdings Ag	Quinazoline derivatives and their use in the treatment of thrombocythemia
US20060030574A1 (en) *	2004-08-04	2006-02-09	Shire Holdings Ag	Quinazoline derivatives useful for the treatment of peripheral arterial disease and as phosphodiesterase inhibitors
CN101137412B (zh)	2005-01-13	2012-11-07	布里斯托尔-迈尔斯·斯奎布公司	用作凝血因子XIa抑制剂的取代的二芳基化合物
MX2007008434A (es)	2005-01-19	2007-07-25	Squibb Bristol Myers Co	Derivados de 2-fenoxi-n-(1,3,4-tiadizol-2il)piridin-3-amina y compuestos relacionados como inhibidores del receptor p2y1 para el tratamiento de trastornos tromboembolicos.
WO2007002634A1 (fr)	2005-06-27	2007-01-04	Bristol-Myers Squibb Company	Antagonistes carbocycliques et heherocycliques du recepteur p2y1, utiles pour traiter des etats pathologiques thrombotiques
WO2007002584A1 (fr)	2005-06-27	2007-01-04	Bristol-Myers Squibb Company	Mimetiques lineaires de l’uree antagonistes du recepteur p2y1, utilises dans le traitement des troubles thrombotiques
ATE485269T1 (de)	2005-06-27	2010-11-15	Bristol Myers Squibb Co	C-verknüpfte zyklische antagonisten des p2y1- rezeptors mit eignung bei der behandlung thrombotischer leiden
AR056867A1 (es)	2005-06-27	2007-10-31	Bristol Myers Squibb Co	Antagonistas heterociclicos n- enlazados del receptor de p2y1 utiles en el tratamiento de condiciones tromboticas. composiciones farmaceuticas.
EP2061756B1 (fr)	2006-06-08	2013-09-25	Bristol-Myers Squibb Company	2-aminocarbonylphenylamino-2-phenyl comme inhibiteurs de facteur viia utiles en tant qu'anticoagulants
US7960569B2 (en)	2006-10-17	2011-06-14	Bristol-Myers Squibb Company	Indole antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions
US7910597B2 (en) *	2006-11-28	2011-03-22	Shire Llc	Substituted quinazolines
US8304420B2 (en)	2006-11-28	2012-11-06	Shire Llc	Substituted quinazolines for reducing platelet count
ES2546815T3 (es)	2006-12-15	2015-09-28	Bristol-Myers Squibb Company	Análogos de arilpropilamida, arilacrilamida, arilpropinamida o arilmetilurea como inhibidores del factor XIa
PE20081775A1 (es)	2006-12-20	2008-12-18	Bristol Myers Squibb Co	Compuestos macrociclicos como inhibidores del factor viia
KR20100037600A (ko)	2007-06-13	2010-04-09	브리스톨-마이어스 스큅 컴퍼니	응고 인자 억제제로서의 디펩티드 유사체
US20090130017A1 (en) *	2007-11-19	2009-05-21	Searete Llc	Targeted short-lived drug delivery
JP5504259B2 (ja)	2008-05-19	2014-05-28	メルク・シャープ・アンド・ドーム・コーポレーション	第ｉｘａ因子阻害剤としての複素環式化合物
SMT202000093T1 (it)	2009-06-16	2020-03-13	Pfizer	Forme di dosaggio di apixaban
EP2462123B1 (fr)	2009-08-04	2013-10-02	Merck Sharp & Dohme Corp.	Dérivés de pyrimidine trisubstitués en positions 4,5,6 en tant qu' inhibiteurs du facteur ixa
JP5844287B2 (ja)	2010-02-11	2016-01-13	ブリストル−マイヤーズスクイブカンパニーＢｒｉｓｔｏｌ−ＭｙｅｒｓＳｑｕｉｂｂＣｏｍｐａｎｙ	第ｘｉａ因子阻害剤としてのマクロ環
TW201311689A (zh)	2011-08-05	2013-03-16	必治妥美雅史谷比公司	作為因子ｘｉａ抑制劑之新穎巨環化合物
TW201319068A (zh)	2011-08-05	2013-05-16	必治妥美雅史谷比公司	作為ｘｉａ因子抑制劑之環狀ｐ１接合劑
IN2014CN02806A (fr)	2011-10-14	2015-07-03	Bristol Myers Squibb Co
IN2014CN02805A (fr)	2011-10-14	2015-07-03	Bristol Myers Squibb Co
LT2766346T (lt)	2011-10-14	2017-06-12	Bristol-Myers Squibb Company	Pakeistieji tetrahidroizochinolino junginiai, kaip faktoriaus xia inhibitoriai
AU2012335220B2 (en)	2011-11-11	2017-06-01	Pfizer Inc.	2-thiopyrimidinones
AU2013245353A1 (en)	2012-04-06	2014-09-25	Pfizer Inc.	Diacylglycerol acyltransferase 2 inhibitors
CA2880898A1 (fr)	2012-08-03	2014-02-06	Bristol-Myers Squibb Company	Recepteurs p1 de la dihydropyridone en tant qu'inhibiteurs du facteur xia
KR20150038372A (ko)	2012-08-03	2015-04-08	브리스톨-마이어스 스큅 컴퍼니	인자 XIa 억제제로서의 디히드로피리돈 P1
JP6479763B2 (ja)	2013-03-25	2019-03-06	ブリストル−マイヤーズスクイブカンパニーＢｒｉｓｔｏｌ−ＭｙｅｒｓＳｑｕｉｂｂＣｏｍｐａｎｙ	第ｘｉａ因子阻害剤としての置換アゾール含有のテトラヒドロイソキノリン
ES2665153T3 (es)	2013-10-09	2018-04-24	Pfizer Inc.	Antagonistas del receptor EP3 de prostaglandina
JP6505727B2 (ja)	2014-01-31	2019-04-24	ブリストル−マイヤーズスクイブカンパニーＢｒｉｓｔｏｌ−ＭｙｅｒｓＳｑｕｉｂｂＣｏｍｐａｎｙ	ヘテロ環式ｐ２’基を有する第ｘｉａ因子阻害剤としてのマクロ環
NO2760821T3 (fr)	2014-01-31	2018-03-10
CU24395B1 (es)	2014-03-17	2019-04-04	Pfizer	Inhibidores de diacilglicerol aciltransferasa 2
PL3536685T3 (pl)	2014-04-04	2022-05-16	Pfizer Inc.	Bicykliczne skondensowane związki heteroarylowe lub arylowe i ich zastosowanie jako inhibitory IRAK4
WO2015160636A1 (fr)	2014-04-16	2015-10-22	Merck Sharp & Dohme Corp.	Inhibiteurs du facteur ixa
NO2721243T3 (fr)	2014-10-01	2018-10-20
SG11201708407TA (en)	2015-05-05	2017-11-29	Pfizer	2-thiopyrimidinones
DK3310784T3 (da)	2015-06-17	2020-11-09	Pfizer	Tricykliske forbindelser og deres anvendelse som phosphodiesterasehæmmere
WO2016203335A1 (fr)	2015-06-18	2016-12-22	Pfizer Inc.	Nouvelles pyrido [2,3-b] pyrazinones utilisées en tant qu'inhibiteurs de bromodomaines de la famille bet
ES2871111T3 (es)	2015-07-29	2021-10-28	Bristol Myers Squibb Co	Inhibidores macrocíclicos del factor XIa que contienen un grupo P2' no aromático
US10336730B2 (en)	2015-08-05	2019-07-02	Bristol-Myers Squibb Company	Substituted glycine derived FXIA inhibitors
HRP20210472T1 (hr)	2015-08-27	2021-05-14	Pfizer Inc.	Biciklički kondenzirani heteroarilni ili arilni spojevi kao modulatori irak4
CN109195973A (zh)	2016-03-02	2019-01-11	百时美施贵宝公司	具有因子xia抑制活性的二酰胺大环类化合物
AR109179A1 (es)	2016-08-19	2018-11-07	Pfizer	Inhibidores de diacilglicerol aciltransferasa 2
JP7161605B2 (ja)	2018-08-31	2022-10-26	ファイザー・インク	Ｎａｓｈ／ｎａｆｌｄおよび関連疾患の治療のための組合せ
CA3140972C (fr)	2019-05-20	2024-06-18	Pfizer Inc.	Combinaisons comprenant du benzodioxol en tant qu'agonistes de glp-1r destinees a etre utilisees dans le traitement de la nash/nafld et de maladies associees
CA3189771A1 (fr)	2020-07-22	2022-01-27	Janssen Pharmaceutica Nv	Composes utiles en tant qu'inhibiteurs du facteur xia
WO2023026180A1 (fr)	2021-08-26	2023-03-02	Pfizer Inc.	Forme amorphe de (s)-2-(5-((3-éthoxypyridin-2-yl)oxy)pyridin-3-yl)-n-(tétrahydrofuran-3-yl)pyrimidine-5-carboxamide
WO2024118524A1 (fr)	2022-11-28	2024-06-06	Cerevel Therapeutics, Llc	Composés d'azaindole et leur utilisation en tant qu'inhibiteurs de phosphodiestérase

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4178368A (en) *	1971-09-30	1979-12-11	Behringwerke Aktiengesellschaft	Method for the treatment of thromboembolism
JPS5325775A (en) *	1976-08-24	1978-03-09	Miller Fluid Power Corp	Module type fluid flow control element
US4082612A (en) *	1976-09-24	1978-04-04	Michael Reese Research Foundation	Plasminogen activator complex
NZ191320A (en) *	1978-09-07	1982-09-14	Beecham Group Ltd	In vivo fibrinolytic enzyme having active site blocked by hydrolytically removable group pharmaceutical compositions

1980
- 1980-10-27 EP EP80303797A patent/EP0028489B1/fr not_active Expired
- 1980-10-27 DE DE8080303797T patent/DE3065190D1/de not_active Expired
- 1980-10-29 ZA ZA00806641A patent/ZA806641B/xx unknown
- 1980-11-03 GR GR63267A patent/GR72121B/el unknown
- 1980-11-04 AR AR283122A patent/AR224786A1/es active
- 1980-11-04 DK DK468880A patent/DK158994C/da not_active IP Right Cessation
- 1980-11-04 IE IE2277/80A patent/IE50174B1/en not_active IP Right Cessation
- 1980-11-04 CA CA000363957A patent/CA1174621A/fr not_active Expired
- 1980-11-04 IL IL61408A patent/IL61408A/xx not_active IP Right Cessation
- 1980-11-04 NO NO803304A patent/NO163867C/no unknown
- 1980-11-05 ES ES496586A patent/ES496586A0/es active Granted
- 1980-11-05 JP JP15573380A patent/JPS5678590A/ja active Granted
- 1980-11-05 HU HU802661A patent/HU185223B/hu not_active IP Right Cessation
- 1980-11-05 NZ NZ195469A patent/NZ195469A/en unknown
1986
- 1986-08-29 US US06/902,429 patent/US4808405A/en not_active Expired - Lifetime
- 1986-09-04 HK HK658/86A patent/HK65886A/en not_active IP Right Cessation
1991
- 1991-12-19 CS CS913911A patent/CS391191A3/cs unknown
- 1991-12-19 CS CS913919A patent/CS391991A3/cs unknown
1993
- 1993-04-22 NL NL930029C patent/NL930029I2/nl unknown

Also Published As

Publication number	Publication date
GR72121B (fr)	1983-09-16
IL61408A (en)	1983-10-31
IE50174B1 (en)	1986-02-19
NO803304L (no)	1981-05-06
EP0028489B1 (fr)	1983-10-05
DK158994B (da)	1990-08-13
NL930029I2 (nl)	1993-12-01
NO163867C (no)	1990-08-01
ZA806641B (en)	1981-10-28
HU185223B (en)	1984-12-28
NZ195469A (en)	1984-05-31
ES8204467A1 (es)	1982-05-01
ES496586A0 (es)	1982-05-01
DK158994C (da)	1991-01-07
IE802277L (en)	1981-05-05
EP0028489A1 (fr)	1981-05-13
AR224786A1 (es)	1982-01-15
AU6401180A (en)	1981-05-14
JPH0316114B2 (fr)	1991-03-04
JPS5678590A (en)	1981-06-27
DK468880A (da)	1981-05-06
NL930029I1 (nl)	1993-06-01
IL61408A0 (en)	1980-12-31
CA1174621A (fr)	1984-09-18
CS391991A3 (en)	1992-06-17
AU534017B2 (en)	1983-12-22
NO163867B (no)	1990-04-23
US4808405A (en)	1989-02-28
DE3065190D1 (en)	1983-11-10
HK65886A (en)	1986-09-12

Publication	Publication Date	Title
CS391991A3 (en)	1992-06-17	Enzyme derivatives, process of their preparation and pharmaceuticals comprising thereof
Schulman et al.	1996	Feasibility of using recombinant factor VIIa in continuous infusion
CA1134295A (fr)	1982-10-26	Derives enzymatiques pour le traitement des thromboses vasculaires
AU784598B2 (en)	2006-05-11	Method of thrombolysis by local delivery of reversibly inactivated acidified plasmin
US6264945B1 (en)	2001-07-24	Parenteral use of bacterial phage associated lysing enzymes for the therapeutic treatment of bacterial infections
EP0196920B1 (fr)	1994-07-06	Espèce dégradée d'activateur de plasminogène tissulaire, composition pharmaceutique et sa méthode de préparation
Klement et al.	1992	The effect of thrombin inhibitors on tissue plasminogen activator induced thrombolysis in a rat model
JPH01193229A (ja)	1989-08-03	抗血液凝固剤
JPH0567278B2 (fr)	1993-09-24
CN1326356A (zh)	2001-12-12	治疗病毒性出血热的方法
JPH04503062A (ja)	1992-06-04	フィブリン溶解
US4507283A (en)	1985-03-26	Pharmacologically active compounds
RU2143490C1 (ru)	1999-12-27	Бифункциональный вариант урокиназы, плазмида, содержащая синтетический структурный ген, кодирующий бифункциональную урокиназу, плазмида (варианты), способ получения плазмиды, способ получения бифункционального варианта урокиназы, тромболитическое средство
JPS5925802A (ja)	1984-02-09	新規なヘパリン化合物
US7063837B2 (en)	2006-06-20	Syrup composition containing phage associated lytic enzymes
Sherry	1987	Thrombolytic therapy in acute myocardial infarction: a perspective
KR0135980B1 (ko)	1998-04-25	플라스미노겐 액티베이터 및 혈전용해제
FI67300B (fi)	1984-11-30	Foerfarande foer framstaellning av in vivo fibrinolytiska enzymderivat foer anvaendning vid behandling ventrombos
JP2002529515A (ja)	2002-09-10	ヘパリンにより誘発される血小板減少症の処置法
US5234686A (en)	1993-08-10	Human tissue plasminogen activator consisting essentially of t-PA residues to 160 to 527, pharmaceutical compositions and methods of treatment
WO1995033471A1 (fr)	1995-12-14	Thrombolyse intravasculaire
JP2002531519A (ja)	2002-09-24	血栓性血小板減少性紫斑病および溶血性尿毒症性症候群の処置法
JP2627950B2 (ja)	1997-07-09	プラスミノーゲンアクチベータ及び血栓溶解剤
WO2012020218A1 (fr)	2012-02-16	Compositions et procédés destinés à induire l'agrégation plaquettaire